Although designed as antidiabetic agents, the cardiovascular and renal benefits conferred by SGLT2 inhibitors and GLP-1 RAs extended the indications to individuals with heart failure and kidney disease without diabetes [8,9,10]. Here, GLP1R is linked to kidney disorder.